-
1 Comment
Pulmatrix, Inc is currently in a long term downtrend where the price is trading 21.9% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.2.
Pulmatrix, Inc's total revenue sank by 99.3% to $13K since the same quarter in the previous year.
Its net income has increased by 100.0% to $-19 since the same quarter in the previous year.
Finally, its free cash flow grew by 314.0% to $10M since the same quarter in the previous year.
Based on the above factors, Pulmatrix, Inc gets an overall score of 3/5.
| CurrencyCode | USD |
|---|---|
| ISIN | US74584P3010 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| Dividend Yield | 0.0% |
|---|---|
| Market Cap | 10M |
| Beta | 0.89 |
| Target Price | 10 |
| PE Ratio | None |
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PULM using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
